Core Insights - Inspira Technologies has successfully deployed its FDA-cleared INSPIRA ART100 system at a premier hospital in New York, marking a significant milestone in the company's deployment plan for cardiopulmonary bypass procedures [1][2][3] - The installation is expected to validate the clinical value of Inspira's innovative approach to extracorporeal life support and establish a commercial presence in the U.S. healthcare market [3][4] - The company aims to revolutionize the $19 billion mechanical ventilation market with its flagship INSPIRA ART500 system, which is designed to replace a significant portion of the estimated 100,000 ventilators in the U.S. with a safer alternative [3][5] Company Overview - Inspira Technologies focuses on developing innovative respiratory support and diagnostic technologies, with its flagship INSPIRA ART500 system enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation [5] - The INSPIRA ART100 system has received regulatory approvals for cardiopulmonary bypass procedures in both the U.S. and Israel, and the company is also developing the HYLA blood sensor technology for continuous blood monitoring [5]

Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update.Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by signific ...

Core Insights - Inspira Technologies announced positive results from its clinical study of the AI-powered HYLA blood sensor, achieving 96% accuracy for a key parameter compared to traditional blood test analyzers [2][3] - The HYLA technology aims to provide continuous, real-time blood monitoring without the need for blood draws, targeting multiple multi-billion-dollar market segments [1][5] - The company plans to submit for FDA approval in the second half of 2025, with the goal of deploying the technology in U.S. hospitals for data collection and post-market validation [4][6] Clinical Study Details - The clinical study involved 6 patients undergoing open-heart surgery, where the HYLA sensor was attached to monitor blood flow during the procedure [2][3] - The HYLA sensor demonstrated 92.3% accuracy in identifying oxygen deficiencies, showcasing its potential for early detection and personalized care [2][3] - Data from the clinical study will be used to enhance the AI algorithms and improve the accuracy of the monitoring system [2][3] Market Potential - The HYLA blood sensor targets the blood gas analyzer market, projected to reach $5.7 billion by 2030, and could strengthen Inspira's position in the $19 billion mechanical ventilation market [5] - The technology is designed for versatility across various clinical settings, including intensive care units and operating rooms, with applications in critical care monitoring and emergency medicine [5][6] Company Overview - Inspira Technologies focuses on developing innovative respiratory support and diagnostic technologies, with its flagship INSPIRA ART system aimed at revolutionizing critical care [6][7] - The company has received regulatory approvals for its INSPIRA ART100 system for cardiopulmonary bypass procedures in the U.S. and Israel [7]